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Abstract
Cytokines and growth factors are important extracellular regulatory proteins. They exert their biological functions through binding to their
cognate receptors on the cell surface and triggering intracellular signaling cascades. However, the intracellular signaling mechanisms of
cytokines and growth factors are not well understood. Accumulating evidence has shown that protein phosphorylation and dephosphorylation
carried out by protein kinases and protein phosphatases are fundamental biochemical events in intracellular signal transduction. SHP-2, a Src
homology (SH) 2 domain-containing protein tyrosine phosphatase (PTP), is widely involved in a variety of signaling pathways triggered by
cytokines and growth factors, including the MAP kinase, Jak-Stat, and PI3 kinase pathways. Recent studies have clearly demonstrated that
this phosphatase plays an important role in transducing signals relayed from the cell surface to the nucleus, and is a critical intracellular
regulator in cytokine and growth factor-induced cell survival, proliferation, and differentiation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cellular responses to a variety of extracellular stimuli
including cytokines and growth factors are mediated by
intracellular signaling pathways. A great deal of evidence
has demonstrated that dysregulation of such signaling path-
ways initiated by extracellular factors causes malfunctioning
of the targeted cells, and this may eventually lead to
diseases. Many important cellular activities, such as cell
survival, proliferation, and differentiation, are highly con-
trolled by the intracellular signal transduction processes in
which protein phosphorylation and dephosphorylation are
central events [1–3]. It is increasingly clear that such
opposing biochemical reactions are carried out by protein
kinases and protein phosphatases. Protein phosphorylation
and dephosphorylation are closely related to the activities of
signaling proteins and directly mediate protein–protein
interactions. Thus, protein tyrosine phosphatases (PTPs),
which dephosphorylate tyrosine phosphorylated signaling
molecules, play equally important roles as protein tyrosine
kinases (PTKs) in transducing signal flow and controlling
cellular behavior. However, compared to PTKs, fewer PTPs
have been identified, and there are limited studies regarding
their signaling mechanisms. SHP-2, an SH2 domain-con-
taining non-transmembrane PTP, is involved in signal trans-
duction of a variety of cytokines and growth factors [4–8]
and plays an important role in regulating cellular biological
responses to external stimuli.
2. Structural basis
SHP-2, previously called SH-PTP2, SH-PTP3, PTP2C,
PTP1D, and Syp, was identified independently by several
groups as a cytosolic SH2 domain-containing PTP [4–8]. It
is ubiquitously expressed in various tissues and cell types,
sharing similar overall structure and high homology with
SHP-1 phosphatase which is predominantly expressed in
hematopoietic cells [9,10]. Both phosphatases contain two
tandem SH2 domains at the N-terminus and one tyrosine
phosphatase domain at the C-terminus. The SH2 domain is a
100-amino-acid motif which mediates the binding of SHP-2
to phosphorylated tyrosine residues on other molecules, thus
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directing specific protein–protein interactions for this phos-
phatase [11]. Normally, SHP-2 phosphatase activity is
repressed and mechanism of its activation is unclear. Earlier
enzymological studies on SHP-1 phosphatase [12–14],
together with the SHP-2 crystal structure studies [15],
indicate that only the N-terminal SH2 domain possesses
auto-inhibitory influence on its catalytic activity. Deletion of
the N-terminus of this phosphatase results in strong catalytic
activation. Occupancy of the N-SH2 domain by phospho-
tyrosine residues leads to an increase in the catalytic activity
of the SHP-2 phosphatase, possibly by inducing a confor-
mational change in the enzyme [15,16]. However, recent
work of Lu et al. [17] argues that both SH2 domains can
contribute to basal repression and consequent activation and
implicates that the C-terminal tyrosine residues are also
involved in SHP-2 activation.
3. Biochemical function in cytokine signaling
Accumulated biochemical data have shown that SHP-2
acts downstream of receptor and cytoplasmic tyrosine
kinases to participate in the signal transduction from the
cell surface to the nucleus. Despite high homology to SHP-1
phosphatase, SHP-2 has completely different functions.
Severe phenotypes observed in motheaten and motheaten
viable mice harboring spontaneous mutations in the SHP-1
gene clearly indicate that SHP-2 cannot replace SHP-1 in
most signaling pathways where they are both involved.
Genetic analyses in Xenopus revealed that both the SH2
domains and the phosphatase domains contribute to signal-
ing, and thus functional specificity of the SHP-2 and SHP-1
phosphatases [18,19].
SHP-2 is widely expressed in various tissues and cell
types and has been implicated in diverse signaling path-
ways including those initiated by growth factors such as
platelet-derived growth factor (PDGF), epidermal growth
factor (EGF), insulin-like growth factor-1 (IGF-1), and
cytokines as interleukin-3 (IL-3), granulocyte macrophage
colony-stimulating factor (GM-CSF), IL-5, erythropoietin
(EPO), IL-6, IL-1, and IL-2, as well as interferon and
insulin [20,21]. SHP-2 has compound signaling functions.
It appears to be involved in a variety of signal trans-
duction processes, such as the Ras-Raf-MAP kinase, Jak-
Stat, PI3 kinase, and NF-nB pathways. Even within a
single signaling pathway, SHP-2 may act at multiple sites
to participate in the signal transduction. For instance, SHP-
2 directly interacts with growth factor and cytokine
receptors, such as PDGF, EGF, stem cell factor (SCF),
and EPO receptors, and becomes rapidly tyrosine phos-
phorylated upon ligand binding. It can also interact with a
variety of signaling intermediates such as Grb2, FRS-2,
Jak2, p85 subunit of PI3 kinase, IRS-1, and Gab1 and 2.
As a PTP, SHP-2 is believed to function by dephosphor-
ylating its associated signaling molecules, thus diminishing
local signals. However, the ultimate effect of SHP-2 in
most signaling pathways is to enhance the signal trans-
duction.
In most circumstances, SHP-2 plays a positive role in
transducing signals relayed from receptor PTKs [18,22–25].
Previous biochemical evidence has demonstrated that the
SHP-2 enzymatic activity is required for its function in
signal transduction [22,26]. Cysteine (Cys) at amino acid
residue 459 has been identified as critical for its phosphatase
activity. While the replacement of cysteine with serine (Ser)
at this site completely abolishes its enzymatic activity, the
capacity for this mutant molecule to bind to other signaling
intermediates via its SH2 domains remains unaltered. It thus
functions as a dominant negative molecule over the endog-
enous wild-type SHP-2. Using this dominant negative
mutant, SHP-2 has been reported, by a number of studies,
to positively regulate the signaling pathways initiated by
insulin, EGF, PDGF, and fibroblast growth factor (FGF)
[22,23,27–30]. Overexpression of this mutant protein has
been shown to block the signaling functions of endogenous
SHP-2 in both in vitro and in vivo models. For instance,
introduction of the catalytically inert SHP-2 molecule
markedly inhibited activation of Erk kinase in response to
EGF, insulin, and fibronectin stimulation [22,23,27–30].
Although the precise biochemical basis for such positive
regulation by this phosphatase in the Erk pathway remains
unclear, it appears that SHP-2 acts in association with the
Grb2–Sos complex. Biochemical studies on csw, the Dro-
sophila homologue of SHP-2, revealed that SHP-2 may
function at a parallel level or upstream of Ras in the MAP
kinase pathway [31]. This notion is subsequently supported
by the results obtained from mammalian cells, as over-
expression of catalytically inactive SHP-2 in 293 cells
significantly inhibits Erk kinase activation and subsequent
Elk-1 transactivation following EGF stimulation. However,
the inactive SHP-2 fails to inhibit Elk-1 transactivation by
activated Ras. Additionally, it has been suggested that SHP-
2 phosphatase also functions as an adaptor protein [32–34].
Our recent studies suggest that SHP-2 promotes IL-3-
induced Jak2 activation in a catalytic-independent manner,
and the conformational changes induced by the physical
association between SHP-2 and Jak2 may contribute to the
positive role of this phosphatase in this respect (unpublished
data).
SHP-2 does play a negative role in certain intracellular
signaling processes. Thus, it may have dual functions in
cytokine and growth factor signal transduction. SHP-2
negatively regulates the Jak-Stat signaling pathway initiated
by interferon-a and -g. As a consequence, mutant cells with
a deletion mutation of SHP-2 are more sensitive to cytotox-
icity of interferons, and activation of downstream Stat2 and
Stat1 is elevated [35]. Another prominent example is that
SHP-2 has been found to diminish the signal relayed from
gp130. We and others have demonstrated that SHP-2
negatively regulates gp130 signaling triggered by leukemia
inhibitory factor, ciliary neurotrophic factor, and IL-6 [36–
40]. Moreover, the recent knock-in mouse model, in which
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the endogenous gp130 has been replaced with a human
gp130 Y759F (equivalent to residue 757 in mouse) mutant
that does not bind to SHP-2, displayed lymphoadenopathy,
splenomegaly, and an enhanced acute-phase immune
response [40]. However, since the data supporting the
negative regulatory role for SHP-2 in this mouse model
were based on enhanced gp130-dependent signaling when
Y757 on gp130, a pivotal binding site for SHP-2, is mutated
to phenylalanine, it remains to be resolved whether these
phenotypes were really mediated by SHP-2. A more recent
report demonstrated that the Y757 was also the recognition
site for suppressor of cytokine signaling-3 (SOCS-3), a
putative SH2 domain containing cytokine signaling sup-
pressor [41]. SOCS-3 and SHP-2 may compete for binding
to this site, and SHP-2 functions to block the effects of
SOCS-3 in the gp130 pathway [41].
SHP-2 is also highly expressed in hematopoietic cells, and
has been indicated to be involved in hematopoietic cytokine
signal transduction [42–44]. It has been demonstrated that
SHP-2 participates in the signal transduction from IL-3, EPO,
SCF, GM-CSF, and IL-5. However, compared to SHP-1
phosphatase, understanding of the physiological and bio-
chemical functions of SHP-2 in hematopoietic cell signaling
is limited. A potential role for SHP-2 phosphatase in hema-
topoietic cytokine signaling is indicated by indirect evidence
based on receptor-mediated changes in SHP-2 tyrosine phos-
phorylation and/or its association with receptors or other
signaling intermediates. Unfortunately, the cellular signifi-
cance of SHP-2 involvement in these cytokine signaling
pathways remains to be further elucidated. This could be
achieved through the signal transduction studies on the
mutant hematopoietic cell lines lacking this phosphatase.
Thus, direct evidence showing SHP-2 biological functions
and the biochemical significance of its enzymatic activity
remains to be obtained.
Identification of the downstream targets or substrates of
SHP-2 will help to elucidate the biochemical basis of SHP-2
activity in cytokine signal transduction. To date, several
such molecules have been identified, such as SHPS-1 [45],
PZR [46], and the newly characterized pleckstrin homology
domain-containing scaffolding or docking proteins, Gab1
[47] and Gab2 [48 – 50]. Tyrosine phosphorylation
responses of these potential substrates in catalytically inac-
tive SHP-2 overexpressing cells stimulated by cytokines are
significantly elevated. In fact, Gab2 was originally identi-
fied to be a major SHP-2-binding protein in IL-3-stimulated
hematopoietic cells [51]. Subsequently, the strong associa-
tion between SHP-2 and Gab2 was further demonstrated to
be induced by thrombopoietin (TPO) and EPO as well as
TCR engagement [50]. In addition, the SHP-2/Gab2 com-
plex is also assembled in hematopoietic cells following h1
integrin cross-linking [52]. Although the SHP-1/Gab2 asso-
ciation was not detected in the earlier studies [51], our [52]
and others’ [53] recent results have showed that SHP-1 also
associates with Gab2. However, unlike the SHP-2/Gab2
association, SHP-1 and Gab2 are associated through the
C-terminal SH2 domain in a constitutive manner. Thus, both
SHP-2 and SHP-1 phosphatases anchor to the same docking
protein Gab2, which may serve as a linker for the functional
interaction between these two enzymes. Even though the
aforementioned potential targets showed strong association
with SHP-2, it appears that they do not represent the
authentic substrates for this phosphatase. None of them
can explain the positive regulation by SHP-2 phosphatase
in cytokine signaling pathways.
4. Biological function in cellular response to cytokine
stimulation
An extensive distribution of SHP-2 phosphatase indicates
that it might have a wide range of physiological functions.
Recent data from SHP-2 gene knock-out mice have clearly
suggested this notion. Mice homozygous for a SHP-2 N-
terminal deletion (amino acids 46–110) mutation exhibit
embryonic lethality. Homozygous mutants die at midgesta-
tion with multiple developmental defects in mesodermal
patterning and body organization [54,55] and this is in
agreement with previous genetic analysis in Xenopus [19].
A similar requirement for SHP-2 in Xenopus development
was found to be attributed to its positive role in basic FGF
signaling [19]. Chimeric mice generated from homozygous
mutant embryonic stem (ES) cells with the deletion muta-
tion of SHP-2 die at various stages, depending on the
contribution from the mutant cells [56]. This strategy has
proven to be an efficient alternative approach for further
defining the physiological functions that are masked due to
the early embryonic lethality of the mutant mice. Several
interesting phenotypes were observed in the chimeric mice
containing SHP-2 mutant cells, such as abnormal develop-
ment of the skeleton and limbs [56,57] and 50% of the
chimeric mice had an open eyelid phenotype. As defective
eyelid development is a typical phenotype of EGF receptor
knock-out mice, this observation suggests that SHP-2 is
required for the in vivo action of EGF. Further genetic
analyses showed that a SHP-2 heterozygous mutation dom-
inantly enhanced the phenotypes of EGF receptor weak
allele (wa-2/wa-2) toward EGF receptor null mutant mice.
Reducing SHP-2 protein level by half significantly dimin-
ished further the EGF signaling on the background of the
EGF receptor point mutation [58]. Subsequently, Chen et al.
[59] showed that the incidence and severity of the defective
cardiac semilunar valvulogenesis was enhanced in wa-2/wa-
2 mice with a heterozygous mutation of SHP-2, further
indicating a functional requirement for SHP-2 in EGF
signaling.
In vitro studies have also revealed that SHP-2 plays
critical roles in regulating a number of cellular activities.
ES cells are totipotent embryonic stem cells, which can be
induced to differentiate into a variety of cell lineages,
including hematopoietic cells, cardiomyocytes, and even
neuronocytes. SHP-2 deletion mutation in such stem cells
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severely decreased erythroid lineage differentiation, and
myeloid lineage development was completely blocked
[60]. Consistent with the in vitro observations, in vivo
hematopoietic progenitor development of mutant ES cell
origin in the bone marrow and fetal liver from the chimeric
mice generated from homozygous mutant ES cells was
undetectable [56]. Further hematopoietic progenitor analysis
of the yolk sac, the earliest embryonic hematopoietic tissue,
demonstrated that hematopoietic activity in SHP-2 mutant
yolk sac was dramatically decreased, suggesting that the
SHP-2 mutation blocks hematopoietic development at the
primitive hematopoiesis stage. Moreover, SHP-2 is also
required for lymphoid lineage development, as SHP-2
mutation completely blocked T and B lymphocyte develop-
ment of the mutant ES cells in SHP-2 / /RAG-2 /
chimeric mice. Thy+ T cells and B220+ B cells derived from
the mutant ES cells were not detected, suggesting that T and
B lymphocyte development was blocked at the Pro-T and
Pro-B stages [61]. It appears that these developmental
defects occur at very early stages in the differentiation
process of ES cells. Indeed, SHP-2 mutation significantly
reduces ES cell differentiation potential [37,39]. The in vitro
differentiation of other lineages, including cardiomyocytes
and fibroblasts from mutant ES cells, was also dramatically
decreased. Since hematopoietic cell development and other
in vivo cellular processes are tightly regulated by extrac-
ellular growth factors and cytokines, all of these data taken
together strongly suggest an indispensable role for SHP-2
phosphatase in the signal transduction of some growth
factors and cytokines.
In contrast to SHP-2 phosphatase, the related SHP-1
phosphatase negatively regulates cytokine signaling [62–
65]. Functional studies on SHP-1 phosphatase has been
considerably facilitated by analyses of motheaten (me/me)
and viable motheaten (mev/mev) mice containing spontane-
ous mutations in the coding region for the N-terminal SH2
domain and the catalytic domain of SHP-1, respectively
[66,67]. Homozygous mutants have obvious hematological
abnormalities. Both me/me and mev/mev mice develop sys-
temic autoimmune disease and die after approximately 3 and
9 weeks, respectively [68]. High levels of immunoglobulins,
particularly autoantibodies in peripheral blood, excessive
erythropoiesis in spleen, and dramatically enhanced cell
growth in response to hematopoietic growth factor stimula-
tion suggest a primarily negative regulatory role for this
phosphatase in hematopoietic development and function.
Consistent with this, it has been found that SHP-1 attenuates
signals emanating from receptors for EPO, IL-3, GM-CSF,
and M-CSF, and mediates inhibitory signals triggered by
NK cell inhibitory receptor, TCR, BCR, CD22, and CD72
[62–64,69–71]. Taken together, these findings suggest that
SHP-2 and the related SHP-1 phosphatase have opposing
functions in regulating cytokine signaling, despite sharing
high homology. Indeed, this view is strongly supported by
our recent hematopoietic analyses on the SHP-2/SHP-1
double mutant mice. Defective primitive hematopoiesis
caused by the SHP-2 mutation was partially rescued by an
additional SHP-1 mutation [61]. More recently, we gener-
ated SHP-2, SHP-1 and SHP-2/SHP-1 double mutant prim-
itive hematopoietic cell lines. Preliminary studies using
these cell lines have suggested that SHP-2 plays a dominant
role in determining IL-3-induced hematopoietic cell res-
ponses, overriding the function of SHP-1. Further biochem-
ical analyses revealed that SHP-2 was required for IL-3-
induced Jak2 kinase activation, while SHP-1 negatively
regulates this process (unpublished data).
5. Perspectives
It is clear that SHP-2 tyrosine phosphatase plays critical
roles in regulating a number of cytokine signals and
mediates a variety of cellular biological processes. Never-
theless, many questions regarding the biochemical basis for
its signaling functions still remain to be resolved. Several
prominent questions are: Why does SHP-2, a protein tyro-
sine phosphatase, in most circumstances, play a positive role
in transducing signal from cytokine receptors and what is
the direct biochemical significance of its phosphatase activ-
ity? Identification of its real in vivo substrates would shed
light on its biochemical function. Importantly, several recent
reports have indicated a clinical relevance of SHP-2 phos-
phatase to some human diseases such as Noonan syndrome
[72], neutropenia (Kostmann’s syndrome) [73] and diabetes
[6,74], further emphasizing the importance of studies on the
biochemical functions of this enzyme in cytokine and
growth factor signal transduction. Understanding the mech-
anisms of SHP-2 action may provide novel insights into the
regulation of intracellular signaling network and may lead to
novel molecular therapeutic approaches for certain diseases.
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